## Check for updates

## OPEN ACCESS

EDITED AND REVIEWED BY Pierre De Meyts, Université catholique de Louvain, Belgium

\*CORRESPONDENCE Zhiqiang Huang 🔀 zhiqiang.huang@ki.se

SPECIALTY SECTION

This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology

RECEIVED 21 March 2023 ACCEPTED 21 March 2023 PUBLISHED 28 March 2023

#### CITATION

Huang Z and Cui H (2023) Editorial: Functional epigenetic regulation in metabolic diseases. *Front. Endocrinol.* 14:1190693. doi: 10.3389/fendo.2023.1190693

### COPYRIGHT

© 2023 Huang and Cui. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: Functional epigenetic regulation in metabolic diseases

# Zhiqiang Huang<sup>1,2\*</sup> and Hengmi Cui<sup>3,4</sup>

<sup>1</sup>Medical School, Nanjing University, Nanjing, China, <sup>2</sup>Department of Biosciences and Nutrition, Karolinska Institutet (KI), Stockholm, Sweden, <sup>3</sup>Jiangsu Innovation Institute for Biomedicine, Nanjing, China, <sup>4</sup>Institute of Epigenetics and Epigenomics, Yangzhou University, Yangzhou, China

## KEYWORDS

epigenetics, gene dysfunction, SNPs, DNA methylation, transcription factor, diseases

## Editorial on the Research Topic Functional epigenetic regulation in metabolic diseases

Human metabolism is delicately coordinated by transcription networks and disturbance of such process is closely linked to a range of diseases, including metabolic disorders, autoimmune diseases, and cancer (1–3). Transcriptional alterations are tightly controlled in the chromatin level through epigenetic mechanisms such as histone modification and DNA methylation (4). Epigenetic remodeling is essential not only for the fine-tuned transcriptional waves during developmental process but also play crucial roles to define disease-related transcription signatures. Investigation into these events, including the chromatin modification process and the underlying regulatory mechanisms involving transcription factors and coregulators, will provide valuable insights for therapeutic interventions (5).

DNA methylation is one of the most extensively studied epigenetic marks, and its functional role is well established (6). For instance, using a methylated DNA immunoprecipitation chip (MeDIP-chip) technique in cardiovascular disease cohort, Hu et al. found that changes in DNA methylation levels were associated with several VEGFR signaling pathway genes (*VEGFB*, *PLGF*, *FATP3*, *F2R*, *FATP4*), potentiating their roles as disease biomarkers. Additionally, the author also found calcium signaling pathway genes (*PLCB1*, *CAMK1D*, *DRD5*) were anomalous methylated in participants.

DNA point mutations can occur frequently due to genetic and environmental factors, some of which are significantly associated with diseases such as metabolic disorders (2). Hou et al. reported that frameshift mutations in *KASH5* can lead to infertility in both sexes, by disrupting the interaction of KASH5 and SUN1. As a result, the reproductive development is halted. The discovery could potentially serve as a genetic foundation for the molecular diagnosis of conditions such as azoospermia (NOA), diminished ovarian reserve (DOR), and recurring miscarriages. Similarly, missense mutations (N162D) in exon 3 of *FGF23* are closely associated with hyperphosphatemia familial neoplastic calcinosis (HFTC) by hindering the glycosylation of its protein, as introduced by Zuo et al. The authors found that the mutated FGF23 protein has defective glycosylation levels and protein stability. By utilizing resources from online databases, Wang et al. found that mutations in the *PRKAR1A* gene are linked to hyperthyroidism. In another bladder cancer cohort, Qu et al. found that variations (rs17110453, rs1934951, rs1934953, and rs2275620) in the CYP2C8 gene are closely related to bladder cancer. These findings suggest that these genetic variations could

potentially be used as a novel biomarker for identifying and preventing bladder cancer in population. These examples demonstrate how functional mutations can have profound effects on protein function and disease outcomes.

Transcription factor inactivation can contribute to metabolic disorders and diseases, as demonstrated by recent studies (7). Specifically, the TBX19 gene is critical for brain cognition (8). The mutation (Glu280Asp) in TBX19 is associated with isolated ACTH deficiency (IAD) and cognitive impairment reported by Charnay et al. Additionally, the study found that mutations in the TBX19 gene can occur at multiple sites, with multiple pathological effects. PPARG2 plays a crucial role in fatty acid metabolism and has a strong association with obesity (9, 10). In a biochemical study, Zhang et al. found that niacin can regulate  $\beta$ -cell lipotoxicity through its effects on GPR109A and PPARG2. Incretin drugs have been found to alleviate these effects, although the underlying mechanism is not yet fully understood. One possibility is that niacin modulates the expression of GPR109A and PPARG2 by modifying the affinity of specific transcription factors. According to a clinical study from Yang et al., a decrease in the GRIM-19 gene expression is correlated with autophagy-related proteins such as BECLIN1, LC3BII/I and BNIP3, which have been linked to recurrent spontaneous abortion (RSA). The underlying mechanism behind this association is believed to be attributed to the activation of immune and inflammation-related pathways in THP-1 macrophages. The examples presented demonstrate the importance of transcription factors in the pathogenesis of diseases and underscore the need for further research on their role in disease development. Therefore, further research on transcription factors and their role in disease development is essential for advancing medical knowledge and developing new therapeutic interventions.

While there have been significant efforts in the field of functional epigenetics, uncovering their roles in diseases remains a challenge. More work is required to map tissue- and diseaserelevant epigenetic alterations in the patients and to investigate the regulatory mechanisms underlying such epigenetic signatures. This information will be crucial in developing effective treatments for metabolic diseases, tumors, and innate immune diseases.

# References

1. Kagohara LT, Stein-O'Brien GL, Kelley D, Flam E, Wick HC, Danilova LV, et al. Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. *Brief Funct Genomics* (2018) 17:49–63. doi: 10.1093/bfgp/elx018

2. Barroso I, McCarthy MI. The genetic basis of metabolic disease. Cell (2019) 177:146–61. doi: 10.1016/j.cell.2019.02.024

3. Mazzone R, Zwergel C, Artico M, Taurone S, Ralli M, Greco A, et al. The emerging role of epigenetics in human autoimmune disorders. *Clin Epigenet* (2019) 11:34. doi: 10.1186/s13148-019-0632-2

4. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. *Circulation* (2011) 123:2145–56. doi: 10.1161/CIRCULATIONAHA.110.956839

5. Wang K, Liu H, Hu Q, Wang L, Liu J, Zheng Z, et al. Epigenetic regulation of aging: implications for interventions of aging and diseases. *Signal Transduct Target Ther* (2022) 7:374. doi: 10.1038/s41392-022-01211-8

# Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

## Funding

Lilly Young Investigator Award 97081 (to ZH). Study on the Epigenetic Mechanism of Silencing of Tumor Suppressor Genes by Antisense RNAs (Natural Science Foundation of China, No.81372237, to HC).

# Acknowledgments

We would like to thank all the co-authors and especially the editors and reviewers for their time and dedication to this Research Topic.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

6. Takahashi Y, Morales Valencia M, Yu Y, Ouchi Y, Takahashi K, Shokhirev MN, et al. Transgenerational inheritance of acquired epigenetic signatures at CpG islands in mice. *Cell* (2023) 186:715–31.e719. doi: 10.1016/j.cell.2022.12.047

7. Kandula V, Kosuru R, Li H, Yan D, Zhu Q, Lian Q, et al. Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy. *Cardiovasc Diabetol* (2016) 15:44. doi: 10.1186/s12933-016-0361-1

8. Peng C, Sun G, Tang Z, Hou X. Congenital isolated ACTH deficiency caused by TBX19 gene mutation: A family report. *Front Pediatr* (2019) 7:546. doi: 10.3389/fped.2019.00546

9. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue treg cells. *Nature* (2012) 486:549–53. doi: 10.1038/nature11132

10. Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. *J Pharm Pharmacol* (2012) 64:161–71. doi: 10.1111/j.2042-7158.2011.01366.x